pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›LEQEMBI
drug
save

LEQEMBI

updated 6mo ago
by Eisai Co Ltd
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval32 co-mentions · 8 sources
  • druglecanemab32 co-mentions · 8 sources

all catalysts(0)

nothing on the calendar yet

News(10)

  • Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
    Cambridge, U.K.-based TrimTech Therapeutics has linked up with Biogen in a collaboration worth up to $411 million in biobucks to develop protein degraders for neurodegenerative diseases.
    fiercebiotech · 1d ago
  • Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
    This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.
    biospace · 1d ago
  • London biotech Oyster harvests $60M for tau-targeting brain drugs
    Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.
    biopharma_dive · 7d ago
  • Novartis ends BioArctic pact; Two VC firms raise inaugural funds
    Plus news about Teva, Ultragenyx and Specific Biologics. Novartis cans BioArctic collab: The Swiss pharma axed its discovery-stage work with the Swedish biotech, which created the Alzheimer’s drug…
    endpoints · 13d ago
  • Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
    Novartis is discontinuing a neurodegeneration alliance with BioArctic in which the companies aimed to develop a drug candidate that could cross the blood-brain barrier.
    biospace · 13d ago
  • BioArctic left out in the cold as Novartis walks away from $800M neuro collab
    Just 14 months after Novartis signed an $800 million biobucks neuroscience partnership with BioArctic, the Swiss pharma has walked away from the deal.
    fiercebiotech · 14d ago
  • Biogen set up for growth even without M&A but CEO won’t rule it out
    Biogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO…
    biospace · 19d ago
  • Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis
    Growth portfolio products like Leqembi and Spinraza helped drive Biogen to $2.8 billion in revenue for the third quarter.
    biospace · 20d ago
  • Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
    In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.
    biopharma_dive · 1mo ago
  • Chutes & Ladders—Vir looks to Liu to lead late-stage push
    As Vir pushes its lead hepatitis D combo through phase 3 development, the biotech has tapped an experienced medical expert to light the way. David Liu, M.D., Ph.D., is now Vir’s chief medical offic…
    fiercebiotech · 1mo ago
view all news mentions →
brand
LEQEMBI
generic
LECANEMAB-IRMB
Data sources
ClinicalTrials.gov
last refreshed 31m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?